Physician profile
Amber Boyd
NPI 1023438553
$790.34
in general payments reported to CMS, 2019-2025
16 companies · $214 in 2025
The $214 reported for 2025 was more than what 77% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $66.26 · 2021: $28.14 · 2022: $24.84 · 2023: $318 · 2024: $139 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $148.61 | 2023-2025 | |
| Gt Medical Technologies, INC | $140.00 | 2023 | Gammatile |
| Glaxosmithkline, LLC. | $132.92 | 2025 | Nucala, Bexsero, Penmenvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.19 | 2023-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.83 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $46.61 | 2020-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $26.51 | 2024 | Ultomiris |
| Melinta Therapeutics, LLC | $25.84 | 2024 | Orbactiv |
| Genzyme Corporation | $25.68 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.84 | 2022 | |
| Abbott Laboratories | $22.87 | 2023 | Freestyle Libre |
| Gilead Sciences, INC. | $20.53 | 2023 | |
| Boston Scientific Corporation | $18.48 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.51 | 2023 | Eliquis |
| Amarin Pharma, INC. | $16.65 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.